Glaucoma: now and beyond
- PMID: 37742700
- DOI: 10.1016/S0140-6736(23)01289-8
Glaucoma: now and beyond
Abstract
The glaucomas are a group of conditions leading to irreversible sight loss and characterised by progressive loss of retinal ganglion cells. Although not always elevated, intraocular pressure is the only modifiable risk factor demonstrated by large clinical trials. It remains the leading cause of irreversible blindness, but timely treatment to lower intraocular pressure is effective at slowing the rate of vision loss from glaucoma. Methods for lowering intraocular pressure include laser treatments, topical medications, and surgery. Although modern surgical innovations aim to be less invasive, many have been introduced with little supporting evidence from randomised controlled trials. Many cases remain undiagnosed until the advanced stages of disease due to the limitations of screening and poor access to opportunistic case finding. Future research aims to generate evidence for intraocular pressure-independent neuroprotective treatments, personalised treatment through genetic risk profiling, and exploration of potential advanced cellular and gene therapies.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests HJ has consulted for Allergan, Ivantis, Scope Ophthalmics, and Rebio; received honoraria for lectures and educational events from Allergan, Laboratoires Théa, and Santen; received support to attend meetings from Allergan; participated on an Advisory Board for Allergan; and has been supported (contribution to salary) by the Moorfields Eye Charity. MK is employed by Copenhagen University Hospital and the University of Copenhagen, and has received funding from the Synoptik Foundation, the Velux Foundation, and Fight for Sight, Denmark. DSF receives institutional grant support from Genentech and the US NIH; has received honoraria for lectures from Laboratoires Théa and Bausch and Lomb; has received support to attend meetings from Laboratoires Théa; is a member of the board of directors of Orbis International; and receives funding from the National Eye Institute and the Harvard Catalyst. GG has received unrestricted research grants from Laboratoires Théa and Santen; has consulted for Allergan, Belkin, Equinox, Genentech, Glaukos, Ivantis, McKinsey, Reichert, Santen, Sight Sciences, and Laboratoires Théa; has received support for attending meetings from Ivantis and Laboratoires Théa; and is a clinical advisor to the Patient Advocacy Group of Glaucoma UK. GG is employed by UCL and has been supported by grants from the National Institute for Health Research (HTA 09/104/40), Moorfields Eye Charity, British Council to Prevent Blindness, Fight For Sight, and the International Glaucoma Association (now known as Glaucoma UK).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical